Pathology Analysis & Statistics, September 2014 (p2)

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Publishers

All regions

You might be interested in: Cancer, Breast Cancer, Leukemia, more »

31-80 of about 4 300 reports

Purchase Reports From Reputable Market Research Publishers

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Kadcyla (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Kadcyla (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, China, United States, United Kingdom, Europe
Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Tykerb (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tykerb (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, China, Europe, United States, United Kingdom
Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • September 2014
  • by Global Data

Neratinib (HER2-Positive Breast Cancer) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Neratinib (HER2-Positive Breast Cancer) - Forecast ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, China, World, United States, United Kingdom, Europe
Flovent (Asthma) - Forecast and Market Analysis to 2023

Flovent (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Flovent (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Flovent (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan
Pulmicort (Asthma) - Forecast and Market Analysis to 2023

Pulmicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Pulmicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Pulmicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Advair (Asthma) - Forecast and Market Analysis to 2023

Advair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Advair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Advair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Symbicort (Asthma) - Forecast and Market Analysis to 2023

Symbicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Symbicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Symbicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : World, Australia, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom
Dulera (Asthma) - Forecast and Market Analysis to 2023

Dulera (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Dulera (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Dulera (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : World, United States
Fostair (Asthma) - Forecast and Market Analysis to 2023

Fostair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Fostair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Fostair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, World, United Kingdom, Europe
Xolair (Asthma) - Forecast and Market Analysis to 2023

Xolair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Xolair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Xolair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Spiriva (Asthma) - Forecast and Market Analysis to 2023

Spiriva (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Spiriva (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Spiriva (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Fluticasone Furoate (Asthma) - Forecast and Market Analysis ...

  • Industries : Pathology
  • Countries : Japan, Australia, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023

Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Bosatria (Mepolizumab) (Asthma) - Forecast and Market ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023

Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Benralizumab (Asthma) - Forecast and Market Analysis to 2023

Benralizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Benralizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Benralizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Dupilumab (Asthma) - Forecast and Market Analysis to 2023

Dupilumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Dupilumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Dupilumab (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Quilizumab (Asthma) - Forecast and Market Analysis to 2023

Quilizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Quilizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Quilizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tralokinumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Diabetes, Metabolic Syndrome and Cardiovascular Disease

Diabetes, Metabolic Syndrome and Cardiovascular Disease

  • $ 3 400
  • Industry report
  • November 2014
  • by TriMark Publications

There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes ...

  • Industries : Pathology
  • Countries : World, United States
Global Influenza Market 2014-2018

Global Influenza Market 2014-2018

  • $ 3 000
  • Industry report
  • October 2014
  • by Infiniti Research Limited

About Influenza Influenza is a contagious respiratory disease caused by influenza viruses. These viruses infect the nose, throat, and lungs causing mild to severe illness. The disease can be fatal in some ...

  • Industries : Pathology
  • Countries : World
North America Autoimmune Diagnostics Market - Growth, Trends And Forecasts (2014 - 2019)

North America Autoimmune Diagnostics Market - Growth, Trends And Forecasts (2014 - 2019)

  • $ 3 000
  • Industry report
  • September 2014
  • by Mordor Intelligence LLP

North America autoimmune disease diagnostics market is estimated to reach $7.09 billion in 2020 from $5.504 billion in 2014 with a CAGR 5.24%. The term “autoimmune disease” ...

  • Industries : Pathology
  • Countries : North America
Global Hepatitis C Market 2014-2018

Global Hepatitis C Market 2014-2018

  • $ 3 000
  • Industry report
  • September 2014
  • by Infiniti Research Limited

About Hepatitis C Hepatitis C is a liver disease caused by infection due to hepatitis C virus. Hepatitis C infection predominantly affects the liver; however, other parts of the body are also affected ...

  • Industries : Pathology
  • Countries : World
PharmaPoint: Asthma - Current and Future Players

PharmaPoint: Asthma - Current and Future Players

  • $ 2 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Asthma - Current and Future Players”. The report is a vital source of up-to-date information ...

  • Industries : Pathology
  • Countries : World
Global Epilepsy Market 2014-2018

Global Epilepsy Market 2014-2018

  • $ 2 500
  • Industry report
  • November 2014
  • by Infiniti Research Limited

About Epilepsy Epilepsy is defined as a spectrum of brain disorders varying from benign symptoms to severe, disabling, and life-threatening symptoms. It can be caused by various factors ranging from brain ...

  • Industries : Pathology
  • Countries : World
Global Fabry Disease Market 2015-2019

Global Fabry Disease Market 2015-2019

  • $ 2 500
  • Industry report
  • November 2014
  • by Infiniti Research Limited

About Fabry Disease Fabry disease is an inheritable lysosomal storage disease characterized by the excessive accumulation of globotriaosylceramide (GL-3) in lysosomes. It results from a deficiency of a-Gal ...

  • Industries : Pathology
  • Countries : World
Global Acne Market 2014-2018

Global Acne Market 2014-2018

  • $ 2 500
  • Industry report
  • November 2014
  • by Infiniti Research Limited

About Acne Acne is one of the common dermatological disorders. Acne, or acne vulgaris is an inflammatory disorder of the skin which affects people of almost all age groups. The exact etiology of acne is ...

  • Industries : Pathology
  • Countries : World
Cutaneous Lupus Erythematosus Global Clinical Trials Review, H2, 2014

Cutaneous Lupus Erythematosus Global Clinical Trials Review, H2, 2014

  • $ 2 500
  • Industry report
  • October 2014
  • by Global Data

Cutaneous Lupus Erythematosus Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Cutaneous Lupus Erythematosus Global Clinical Trials Review, H2, 2014" provides data ...

  • Industries : Pathology
  • Countries : World
Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Global Clinical Trials Review, H2, 2014

Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Global Clinical Trials Review, H2, 2014

  • $ 2 500
  • Industry report
  • October 2014
  • by Global Data

Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Chronic Cutaneous Lupus Erythematosus ...

  • Industries : Pathology
  • Countries : World
About 31 000 reports

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the US

  • Sociologist Pens Book Exploring History of Migraines and Politic...
  • November 2014
    3 pages
  • Migraine  

    Neurological Di...  

  • United States  

View report >

About 200 Companies

Read our Company Profiles

Pfizer Inc.

United States

GlaxoSmithKline PLC

United Kingdom

Novartis Inc.

Switzerland

GlaxoSmithKline P.L.C.

United States

Imaging Systems L.L.C.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.